{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:01:23Z","timestamp":1792728083890,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012680","name":"Universit\u00e4tsklinikum Hamburg-Eppendorf","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"ERC","doi-asserted-by":"publisher","award":["834974"],"award-info":[{"award-number":["834974"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.trecan.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:30:22Z","timestamp":1779276622000},"page":"838-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epithelial\u2013mesenchymal plasticity in breast cancer: from cell states to clinical vulnerability"],"prefix":"10.1016","volume":"12","author":[{"given":"Tingjie","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2772","authenticated-orcid":false,"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-9511","authenticated-orcid":false,"given":"Daniel J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.04.008_bb0005","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2026.04.008_bb0010","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1039\/D4NA00086B","article-title":"Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies","volume":"6","author":"Chaudhari","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.trecan.2026.04.008_bb0015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.04.008_bb0020","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.cell.2025.08.033","article-title":"Epithelial-mesenchymal transition","volume":"188","author":"Zhang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.04.008_bb0025","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-21-4370","article-title":"Epithelial-mesenchymal plasticity in tumor immune evasion","volume":"82","author":"Mullins","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0030","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1038\/s41467-022-32523-6","article-title":"Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence","volume":"13","author":"Aouad","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.008_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41571-025-01058-2","article-title":"EMT and cancer: what clinicians should know","volume":"22","author":"Thompson","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2015.73","article-title":"Clinical management of breast cancer heterogeneity","volume":"12","author":"Zardavas","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0045","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.3390\/cancers15235605","article-title":"Cellular plasticity in mammary gland development and breast cancer","volume":"15","author":"Wicker","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/biomedicines6010020","article-title":"Immune landscape of breast cancers","volume":"6","author":"Nagarajan","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.trecan.2026.04.008_bb0055","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982821","article-title":"SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC","volume":"13","author":"Hasmim","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0065","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/cancers13051165","article-title":"Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer","volume":"13","author":"Xiao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0070","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3390\/cancers16162906","article-title":"Elevated GRHL2 imparts plasticity in ER-positive breast cancer cells","volume":"16","author":"Zheng","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12964-018-0259-5","article-title":"Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence","volume":"16","author":"Tivari","year":"2018","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.trecan.2026.04.008_bb0080","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1038\/s41467-024-54621-3","article-title":"Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial","volume":"15","author":"Rediti","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.008_bb0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ijc.32859","article-title":"Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer","volume":"147","author":"Sonnenblick","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12195-021-00694-9","article-title":"Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis","volume":"15","author":"Buyuk","year":"2022","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.trecan.2026.04.008_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","article-title":"Transcriptional regulation of EMT transcription factors in cancer","volume":"97","author":"Saitoh","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0100","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1158\/0008-5472.CAN-08-1942","article-title":"A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition","volume":"68","author":"Bracken","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0105","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/0008-5472.CAN-20-2626","article-title":"EMT transcription factor ZEB1 represses the mutagenic POL\u03b8-mediated end-joining pathway in breast cancers","volume":"81","author":"Prodhomme","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-021-06256-x","article-title":"ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism","volume":"189","author":"Burks","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2026.04.008_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2024.04.001","article-title":"Alternative splicing in EMT and TGF-\u03b2 signaling during cancer progression","volume":"101","author":"Zhang","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41540-024-00378-w","article-title":"Comprehensive molecular interaction map of TGF\u03b2 induced epithelial to mesenchymal transition in breast cancer","volume":"10","author":"Gottumukkala","year":"2024","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.trecan.2026.04.008_bb0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","article-title":"Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0130","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/ijms19072011","article-title":"Crosstalk between Notch, HIF-1\u03b1 and GPER in breast cancer EMT","volume":"19","author":"De Francesco","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2026.04.008_bb0135","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1158\/0008-5472.CAN-13-3659","article-title":"A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition","volume":"74","author":"Carmona","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trsl.2014.04.001","article-title":"Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells","volume":"165","author":"Nickel","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0145","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1756-0500-3-219","article-title":"Role of DNA methylation in miR-200c\/141 cluster silencing in invasive breast cancer cells","volume":"3","author":"Neves","year":"2010","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.trecan.2026.04.008_bb0150","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3892\/or.2014.3224","article-title":"Reduced BMP6 expression by DNA methylation contributes to EMT and drug resistance in breast cancer cells","volume":"32","author":"Liu","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.trecan.2026.04.008_bb0155","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41598-023-29712-8","article-title":"Epigenetic alterations impede epithelial-mesenchymal transition by modulating centrosome amplification and Myc\/RAS axis in triple negative breast cancer cells","volume":"13","author":"Das","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.04.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188901","article-title":"Epigenetic regulation of cancer-associated fibroblast heterogeneity","volume":"1878","author":"Kehrberg","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0165","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","article-title":"Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas","volume":"77","author":"Dongre","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0170","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/2159-8290.CD-20-0603","article-title":"Direct and indirect regulators of epithelial-mesenchymal transition-mediated immunosuppression in breast carcinomas","volume":"11","author":"Dongre","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.04.008_bb0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2340\/1651-226X.2024.33008","article-title":"The tumor immune microenvironment in breast cancer progression","volume":"63","author":"Otterlei Fj\u00f8rtoft","year":"2024","journal-title":"Acta Oncol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-015-0421-2","article-title":"Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells","volume":"14","author":"Alsuliman","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","article-title":"Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era","volume":"60","author":"Mando","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.trecan.2026.04.008_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131458","article-title":"PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2026.04.008_bb0195","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.7150\/ijbs.15943","article-title":"Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway","volume":"12","author":"Gan","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.trecan.2026.04.008_bb0200","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.953418","article-title":"Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages","volume":"3","author":"Su","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.04.008_bb0205","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/0008-5472.CAN-09-4041","article-title":"Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells","volume":"70","author":"Reiman","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0210","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1158\/0008-5472.CAN-12-2432","article-title":"Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis","volume":"73","author":"Akalay","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0215","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12079-019-00508-8","article-title":"TGF-\u03b21 and TNF-\u03b1 synergistically induce epithelial to mesenchymal transition of breast cancer cells by enhancing TAK1 activation","volume":"13","author":"Liao","year":"2019","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.trecan.2026.04.008_bb0220","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cancers14020285","article-title":"Breast cancer tumor microenvironment and molecular aberrations hijack tumoricidal immunity","volume":"14","author":"Lin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0225","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.04.008_bb0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","article-title":"Epithelial-to-mesenchymal transition in cancer: complexity and opportunities","volume":"12","author":"Zhang","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.trecan.2026.04.008_bb0235","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1228522","article-title":"Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.04.008_bb0240","doi-asserted-by":"crossref","first-page":"17807","DOI":"10.1038\/s41598-019-54282-z","article-title":"A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer","volume":"9","author":"Block","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.04.008_bb0245","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41467-020-15574-5","article-title":"Re-definition of claudin-low as a breast cancer phenotype","volume":"11","author":"Fougner","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.008_bb0250","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41467-020-17249-7","article-title":"Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution","volume":"11","author":"Pommier","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7571","article-title":"Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin","volume":"14","author":"Grasset","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.04.008_bb0260","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf6063","article-title":"An EMT\u2013primary cilium\u2013GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis","volume":"7","author":"Wilson","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.04.008_bb0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41419-023-05591-9","article-title":"NF-YAl drives EMT in Claudinlow tumours","volume":"14","author":"Londero","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2026.04.008_bb0275","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/cancers15071974","article-title":"Immune checkpoint and EMT-related molecules in circulating tumor cells (CTCs) from triple negative breast cancer patients and their clinical impact","volume":"15","author":"Vardas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0280","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/s41467-022-29723-5","article-title":"Cooperative interaction between ER\u03b1 and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis","volume":"13","author":"Mohammadi Ghahhari","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.04.008_bb0285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41523-024-00688-6","article-title":"GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer","volume":"10","author":"Sandstrom","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0290","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/2159-8290.CD-23-1161","article-title":"Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells","volume":"14","author":"Rosano","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.04.008_bb0295","doi-asserted-by":"crossref","first-page":"8640","DOI":"10.3390\/ijms25168640","article-title":"Targeting ITG\u03b23 to overcome trastuzumab resistance through epithelial-mesenchymal transition regulation in HER2-positive breast cancer","volume":"25","author":"Boz Er","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trecan.2026.04.008_bb0300","doi-asserted-by":"crossref","first-page":"15821","DOI":"10.1038\/srep15821","article-title":"Trastuzumab resistance induces EMT to transform HER2+ PTEN\u2212 to a triple negative breast cancer that requires unique treatment options","volume":"5","author":"Burnett","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.04.008_bb0305","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.04.008_bb0310","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1073\/pnas.1120068109","article-title":"Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors","volume":"109","author":"Gurney","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.04.008_bb0315","doi-asserted-by":"crossref","first-page":"41794","DOI":"10.18632\/oncotarget.5993","article-title":"Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun\/COX-2 signaling pathway","volume":"6","author":"Qin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2026.04.008_bb0320","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.4161\/cc.9.18.13131","article-title":"Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status","volume":"9","author":"Vazquez-Martin","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trecan.2026.04.008_bb0325","doi-asserted-by":"crossref","first-page":"40907","DOI":"10.18632\/oncotarget.5723","article-title":"Disulfiram inhibits TGF-\u03b2-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK\/NF-\u03baB\/Snail pathway","volume":"6","author":"Han","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2026.04.008_bb0330","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial\u2013mesenchymal transition (EMT) to mesenchymal\u2013epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0335","series-title":"Molecular Imaging and Contrast Agent Database (MICAD) [Internet]","article-title":"89Zr-Labeled fresolimumab (human anti-transforming growth factor-\u03b2 monoclonal antibody) 2011 Dec 13 [Updated 2012 Jan 26]","author":"Chopra","year":"2004"},{"key":"10.1016\/j.trecan.2026.04.008_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1443422","article-title":"Effects of BYL-719 (alpelisib) on human breast cancer stem cells to overcome drug resistance in human breast cancer","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0345","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2478\/raon-2022-0012","article-title":"Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer","volume":"56","author":"Choi","year":"2022","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0350","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3892\/ijo.2016.3337","article-title":"WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells","volume":"48","author":"Xu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0355","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s12885-020-07555-0","article-title":"Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation","volume":"20","author":"Wei","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0360","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/cancers11081050","article-title":"PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer","volume":"11","author":"Saleh","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0365","article-title":"Curcumin suppresses metastasis of triple-negative breast cancer cells by modulating EMT signaling pathways: an integrated study of bioinformatics analysis","volume":"103","author":"Chen","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trecan.2026.04.008_bb0370","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mc.23234","article-title":"Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer","volume":"59","author":"Alraouji","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.trecan.2026.04.008_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk2746","article-title":"Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer","volume":"8","author":"Adam-Artigues","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.04.008_bb0380","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41419-026-08435-4","article-title":"TGF\u03b2 signaling promotes cell cycle progression and resistance to the CDK4\/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells","volume":"17","author":"Ali","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2026.04.008_bb0385","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.04.008_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd7455","article-title":"Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells","volume":"7","author":"Guo","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.04.008_bb0395","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.008_bb0400","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.04.008_bb0405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0410","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.04.008_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101258","article-title":"Circulating tumor cells as liquid biopsy markers in cancer patients","volume":"96","author":"Smit","year":"2024","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.trecan.2026.04.008_bb0420","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10585-024-10267-5","article-title":"Clinical applications of circulating tumor cells in patients with solid tumors","volume":"41","author":"Smit","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.trecan.2026.04.008_bb0425","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.04.008_bb0430","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s43018-020-0068-9","article-title":"Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis","volume":"1","author":"Lo","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.04.008_bb0435","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.04.008_bb0440","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1535-7163.MCT-18-0584","article-title":"Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer","volume":"18","author":"Papadaki","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.04.008_bb0445","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/2159-8290.CD-25-0164","article-title":"From discovery to diagnosis: a perspective for circulating tumor cells in personalized oncology","volume":"15","author":"Alix-Panabieres","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.04.008_bb0450","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: from exploration to practical application","volume":"43","author":"Alix-Panabieres","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.04.008_bb0455","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","article-title":"Circulating tumor cells in breast cancer: clinical validity and utility","volume":"10","author":"Thomas-Bonafos","year":"2024","journal-title":"NPJ Breast Cancer"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:44:58Z","timestamp":1788986698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2405803326000841"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.04.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epithelial\u2013mesenchymal plasticity in breast cancer: from cell states to clinical vulnerability","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}